Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Seefat RL, Vliek SB, de Jong VMT, Balduzzi S, Mandjes IA, Retèl VP, Eekhout I, Delfos M, Schot M, Holtkamp MJ, van Rosmalen MM, Leeneman B, Blommestein H, Huitema ADR, Rosenberg EH, Nederlof PM, Chan TWS, van Rhenen A, Wondergem MJ, Schaap NPM, Snijders TJF, Van der Poel MWM, Plattel WJ, van Werkhoven E, van Tinteren H, Smidt ML, Wesseling J, Jonkers J, Rottenberg S, Vrancken Peeters MTFD, Voermans C, Maduro JH, Kroep JR, Schroder CP, Kuip EJM, Gonçalves A, Nuver J, Wymenga ANM, Bijlsma RM, van der Wall E, Konings IRHM, Tjan-Heijnen VCG, Jongen-Lavrencic M, Jager A, Linn SC

Open source

DOI: 10.1016/s1470-2045(26)00131-2
Published: 2026 Jul
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00131-2,
  title = {Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.},
  author = {Seefat RL and Vliek SB and de Jong VMT and Balduzzi S and Mandjes IA and Retèl VP and Eekhout I and Delfos M and Schot M and Holtkamp MJ and van Rosmalen MM and Leeneman B and Blommestein H and Huitema ADR and Rosenberg EH and Nederlof PM and Chan TWS and van Rhenen A and Wondergem MJ and Schaap NPM and Snijders TJF and Van der Poel MWM and Plattel WJ and van Werkhoven E and van Tinteren H and Smidt ML and Wesseling J and Jonkers J and Rottenberg S and Vrancken Peeters MTFD and Voermans C and Maduro JH and Kroep JR and Schroder CP and Kuip EJM and Gonçalves A and Nuver J and Wymenga ANM and Bijlsma RM and van der Wall E and Konings IRHM and Tjan-Heijnen VCG and Jongen-Lavrencic M and Jager A and Linn SC},
  year = {2026},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(26)00131-2},
  url = {https://doi.org/10.1016/s1470-2045(26)00131-2}
}

RIS

TY  - JOUR
TI  - Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.
AU  - Seefat RL
AU  - Vliek SB
AU  - de Jong VMT
AU  - Balduzzi S
AU  - Mandjes IA
AU  - Retèl VP
AU  - Eekhout I
AU  - Delfos M
AU  - Schot M
AU  - Holtkamp MJ
AU  - van Rosmalen MM
AU  - Leeneman B
AU  - Blommestein H
AU  - Huitema ADR
AU  - Rosenberg EH
AU  - Nederlof PM
AU  - Chan TWS
AU  - van Rhenen A
AU  - Wondergem MJ
AU  - Schaap NPM
AU  - Snijders TJF
AU  - Van der Poel MWM
AU  - Plattel WJ
AU  - van Werkhoven E
AU  - van Tinteren H
AU  - Smidt ML
AU  - Wesseling J
AU  - Jonkers J
AU  - Rottenberg S
AU  - Vrancken Peeters MTFD
AU  - Voermans C
AU  - Maduro JH
AU  - Kroep JR
AU  - Schroder CP
AU  - Kuip EJM
AU  - Gonçalves A
AU  - Nuver J
AU  - Wymenga ANM
AU  - Bijlsma RM
AU  - van der Wall E
AU  - Konings IRHM
AU  - Tjan-Heijnen VCG
AU  - Jongen-Lavrencic M
AU  - Jager A
AU  - Linn SC
PY  - 2026
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(26)00131-2
UR  - https://doi.org/10.1016/s1470-2045(26)00131-2
ER  -

APA

RL, S., SB, V., VMT, D. J., S, B., IA, M., VP, R., I, E., M, D., M, S., MJ, H., MM, V. R., B, L., H, B., ADR, H., EH, R., PM, N., TWS, C., A, V. R., MJ, W., NPM, S., TJF, S., MWM, V. D. P., WJ, P., E, V. W., H, V. T., ML, S., J, W., J, J., S, R., MTFD, V. P., C, V., JH, M., JR, K., CP, S., EJM, K., A, G., J, N., ANM, W., RM, B., E, V. D. W., IRHM, K., VCG, T., M, J., A, J., & SC, L. (2026). Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00131-2

Source records

pubmed · retrieved 2026-09-25T23:27:10.582Z